ALXO ALX Oncology Holdings Inc.
$1.18▲ +7.27%
Healthcare
Other
After hours
$1.19▲ +0.85%
Oct 28, 6:46 PM ET
Volume 2.94M
Avg Volume (10D) 1.69M
Key Metrics & Fundamentals
Market Cap
$163.17M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.86 - 2.66
% vs 50 MA
-23.63%
% vs 200 MA
-35.36%
RSI-14
45.0
MACD Histogram
+0.0300
Beta (1Y vs SPY)
0.58
Free Cash Flow
-$16.07M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$16.93M
COGS
–
Operating Exp
$18.27M
Operating Income
-$18.27M
EBIT
-$18.27M
Pretax Income
-$17.97M
Net Income
-$17.97M
EPS (Diluted)
-0.13
Price & Volume History
Loading chart…
Recent News
ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer
GlobeNewswire · Sep 28, 2026 8:00 AM ET
Top Premarket Decliners
MT Newswires · Sep 18, 2026 7:43 AM ET
ALX Oncology to Present at Upcoming Investor Conferences in September
GlobeNewswire · Sep 2, 2026 8:00 AM ET
Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year?
Zacks · Aug 11, 2026 9:40 AM ET
ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update
GlobeNewswire · Aug 6, 2026 8:00 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See ALXO's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.